Cardamom for Anti-Inflammatory

Research suggests that cardamom and its bioactive compounds — particularly 1,8-cineole, alpha-terpinyl acetate, and various terpene constituents — demonstrate anti-inflammatory activity across a range of study types, including in vitro cell studies, animal models, narrative and systematic reviews, and a small number of human clinical trials. A 2024 systematic review and meta-analysis pooling eight randomized clinical trials found that cardamom supplementation was associated with significant reductions in inflammatory markers such as hs-CRP, IL-6, and TNF-α, while laboratory and animal studies consistently show that cardamom extracts and essential oils can suppress pro-inflammatory signaling pathways, reduce cytokine production, and modulate immune cell activity. However, the overall body of evidence carries important limitations: human trial data remain sparse and the available studies are small in number and size, a broader 2022 systematic review of functional foods found the clinical evidence for anti-inflammatory effects of foods in this category to be inconclusive overall, and questions around bioavailability and optimal dosing in humans have not been resolved. Studies indicate that cardamom shows genuine promise as a natural anti-inflammatory agent, but researchers consistently call for larger, well-designed clinical trials before firm conclusions can be drawn.